There are currently 5 active clinical trials seeking participants for Thrombocytopenia research studies. The states with the highest number of trials for Thrombocytopenia participants are California, Texas, New York and Ohio.
Collection of Peripheral Blood From Patients With Hematologic Malignancies With Thrombocytopenia
NCT06824727
Recruiting
The purpose of the research project is to collect one blood sample from participants who are affected by very low platelets as a result of their condition or their treatment.
Gender:
ALL
Ages:
Between 18 years and 88 years
Trial Updated:
02/12/2025
Locations: Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio
Conditions: Thrombocytopenia
Register for Updates
Luspatercept for Clonal Cytopenias of Uncertain Significance
NCT06788691
Recruiting
The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Weill Cornell Medical College, New York, New York
Conditions: CCUS Clonal Cytopenia of Undetermined Significance, Anemia, Leukopenia, Thrombocytopenia, Neutropenia
Register for Updates
Apixaban in Thrombocytopenia
NCT06886516
Recruiting
This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes. The name of the study drug involved in this study is: -Apixiban (a type of anticoagulant)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Deep Vein Thrombosis, Pulmonary Embolism and Thrombosis, Thrombocytopenia, Recurrent Venous Thromboembolism
Register for Updates
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
NCT05711485
Recruiting
Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.
Gender:
ALL
Ages:
Between 6 months and 59 months
Trial Updated:
10/29/2024
Locations: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland +1 locations
Conditions: Severe Malaria, Thrombocytopenia
Register for Updates
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT06291415
Recruiting
This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: Childrens Hospital of California, Irvine, California +27 locations
Conditions: Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic, Purpura, Blood Coagulation Disorder, Thrombotic Microangiopathies, Hemorrhagic Disorders, Autoimmune Diseases, Immune System Diseases, Hemorrhage, Pathologic Processes, Skin Manifestations, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, Primary Immune Thrombocytopenia, ITP - Immune Thrombocytopenia
Register for Updates